BACKGROUND: Previous studies suggest an increased risk of cardiovascular disease in psoriasis, but the relative contributions of traditional risk factors and markers of disease severity are unclear. We examined the effect of psoriasis disease characteristics on cardiovascular risk after adjusting for traditional cardiovascular risk factors. METHODS: Study populations included (a) case-cohort sample of 771 patients nested within a population-based psoriasis incidence cohort, and (b) cohort of 1905 patients with incident and prevalent psoriasis patients. Both cohorts were followed-up to ascertain disease and treatment characteristics, traditional cardiovascular risk factors and cardiovascular outcomes. Cox proportional hazards regression models were used to identify predictors of cardiovascular outcomes. RESULTS: After adjusting for traditional risk factors, increasing number of psoriasis-affected body sites at disease onset (HR: 1.53 per additional site, 95% CI: 1.20, 1.95) was significantly associated with an increased risk of cardiovascular outcomes. Phototherapy (HR: 3.76, 95% CI: 2.45, 5.77) and systemic therapy (HR: 2.17, 95% CI: 1.50, 3.13) were associated with a higher risk of cardiovascular outcomes in univariate analyses, but these relatively strong associations disappeared after adjusting for cardiovascular risk factors. CONCLUSIONS: Increasing number of psoriasis-affected body sites may be a severity indicator in psoriasis and is associated with an increased cardiovascular risk. Due to low number of patients exposed to systemic therapy, this study had limited power to examine the effect of treatment on cardiovascular risk. Strong associations with phototherapy and systemic therapy suggest that the cardiovascular risk in psoriasis is confined to patients with severe disease.
BACKGROUND: Previous studies suggest an increased risk of cardiovascular disease in psoriasis, but the relative contributions of traditional risk factors and markers of disease severity are unclear. We examined the effect of psoriasis disease characteristics on cardiovascular risk after adjusting for traditional cardiovascular risk factors. METHODS: Study populations included (a) case-cohort sample of 771 patients nested within a population-based psoriasis incidence cohort, and (b) cohort of 1905 patients with incident and prevalent psoriasispatients. Both cohorts were followed-up to ascertain disease and treatment characteristics, traditional cardiovascular risk factors and cardiovascular outcomes. Cox proportional hazards regression models were used to identify predictors of cardiovascular outcomes. RESULTS: After adjusting for traditional risk factors, increasing number of psoriasis-affected body sites at disease onset (HR: 1.53 per additional site, 95% CI: 1.20, 1.95) was significantly associated with an increased risk of cardiovascular outcomes. Phototherapy (HR: 3.76, 95% CI: 2.45, 5.77) and systemic therapy (HR: 2.17, 95% CI: 1.50, 3.13) were associated with a higher risk of cardiovascular outcomes in univariate analyses, but these relatively strong associations disappeared after adjusting for cardiovascular risk factors. CONCLUSIONS: Increasing number of psoriasis-affected body sites may be a severity indicator in psoriasis and is associated with an increased cardiovascular risk. Due to low number of patients exposed to systemic therapy, this study had limited power to examine the effect of treatment on cardiovascular risk. Strong associations with phototherapy and systemic therapy suggest that the cardiovascular risk in psoriasis is confined to patients with severe disease.
Authors: A D White; A R Folsom; L E Chambless; A R Sharret; K Yang; D Conwill; M Higgins; O D Williams; H A Tyroler Journal: J Clin Epidemiol Date: 1996-02 Impact factor: 6.437
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: F C Ernste; M Sánchez-Menéndez; K M Wilton; C S Crowson; E L Matteson; H Maradit Kremers Journal: Arthritis Care Res (Hoboken) Date: 2015-07 Impact factor: 4.794
Authors: Hilal Maradit-Kremers; Ross A Dierkhising; Cynthia S Crowson; Murat Icen; Floranne C Ernste; Marian T McEvoy Journal: Int J Dermatol Date: 2013-01 Impact factor: 2.736
Authors: Howa Yeung; Joy Wan; Abby S Van Voorhees; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Daniel B Shin; Andrea B Troxel; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2012-07-28 Impact factor: 11.527
Authors: Lihi Eder; Paula Harvey; Vinod Chandran; Cheryl F Rosen; Jan Dutz; James T Elder; Proton Rahman; Christopher T Ritchlin; Sherry Rohekar; Richard Hayday; Snezana Barac; Joy Feld; Devy Zisman; Dafna D Gladman Journal: J Rheumatol Date: 2018-02-01 Impact factor: 4.666
Authors: Priscila Miranda Diogo Mesquita; Augusto Diogo; Miguel Tanus Jorge; Alceu Luiz Camargo Villela Berbert; Sônia Antunes de Oliveira Mantese; José Joaquim Rodrigues Journal: An Bras Dermatol Date: 2017 Jan-Feb Impact factor: 1.896
Authors: Elena Myasoedova; Bharath Manu Akkara Veetil; Eric L Matteson; Hilal Maradit Kremers; Marian T McEvoy; Cynthia S Crowson Journal: Scientifica (Cairo) Date: 2013-01-31